PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular

« Life Science Competition Congress Enhance Competitive and Business Intelligence Platforms, November 16-17, 2015 | Westin Governor Morris | Morristown, NJ

FDA approves a drug manufactured using 3D printing »

PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular

August 4, 2015 by 2012pharmaceutical

UPDATED on 3/16/2019

https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active

Patients with necrotizing autoimmune myopathy from statins may benefit from a PCSK9 inhibitor, a case report from Spain noted in the Annals of Internal Medicine.

PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 3/28/2016

· by Crystal Phend
Senior Associate Editor, MedPage Today

Alirocumab (Praluent) reduced the frequency of apheresis by 75% compared with placebo and eliminated the need for apheresis for 63%, according to top-line results from the 62-patient phase III ODYSSEY ESCAPE trial in heterozygous familial hypercholesterolemia getting the treatments.

SOURCE

http://www.medpagetoday.com/Cardiology/Prevention/56973?isalert=1&uun=g99985d4930R5099207u&xid=NL_breakingnews_2016-03-28

UPDATED on 3/21/2016

The PPAR-delta agonist MBX-8025 was associated with a drop in LDL cholesterol by at least 15% for the majority of genetically-confirmed homozygous familial hypercholesterolemia patients when added to ezetimibe (Zetia) and maximal statin therapy in a small open-label, dose-escalation phase II trial. The company plans a pilot study combining the agent with a PCSK9 inhibitor too.

SOURCE

http://www.medpagetoday.com/Cardiology/Prevention/56832?isalert=1&uun=g99985d4908R5099207u&xid=NL_breakingnews_2016-03-21

CVD = cardiovascular disease;

HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A;

LDL = low-density lipoprotein;

LDL-C = low-density lipoprotein cholesterol;

LDLR = low-density lipoprotein receptor;

PCSK9 = proprotein convertase subtilisin/kexin type 9.

References

Brown MS, Goldstein JL. Proc Natl Acad Sci USA. 1979;76:3330-3337.
Goldstein JL, Brown MS. Arterioscler Thromb Vasc Biol. 2009;29:431-438.
Qian Y-W, Schmidt RJ, Zhang Y, et al. J Lipid Res. 2007;48:1488-1498.
Brown MS, Goldstein JL. Science. 1986;232:34-47.
Horton JD, Cohen JC, Hobbs HH. J Lipid Res. 2009;50(suppl):S172-S177.

VIEW VIDEO

http://www.cholesterolneversleeps.com/what-is-pcsk9.html?WT.z_co=A&WT.z_in=DSY&WT.z_ch=DSPWT.z_ag=AG705&WT.tsrc=DSP&WT.mc_id=DSY_DSP_AG705_DSP

PCSK9 gene mutations can have profound effects on plasmaLDL-C levels¹

PCSK9 Loss of Function Mutations

Increase LDLR levels on the surface of the hepatocyte, which leads to an increase in LDL clearance, resulting in low plasma LDL-C levels^2,3

PCSK9 Gain of Function Mutations

Decrease LDLR levels on the surface of the hepatocyte, which leads to a reduction in LDL clearance, resulting in high plasma LDL-C levels^2,3

PCSK9 and Cholesterol Homeostasis

The Biology of Cholesterol Synthesis and Metabolism

HMG-COA REDUCTASE IS THE RATE-CONTROLLING ENZYME IN CHOLESTEROL BIOSYNTHESIS.¹

Both HMG-CoA reductase and LDLRs are tightly regulated and can be increased or decreased, affecting cholesterol synthesis and homeostasis.²

HMG-CoA
Reductase

Incoming hepatic cholesterol suppresses HMG-CoA reductase, turning off cholesterol synthesis in the cell.¹

LDLR

In addition, LDLR synthesis is turned off, preventing further entry of LDL and protecting cells against an overaccumulation of cholesterol.¹

Recycling of LDLRs enables efficient clearance of plasma LDL particles.²

LDLRs bind to LDL particles and transport them into the hepatocyte. The LDL particles then dissociate from the LDLRs and are broken down. The LDLRs are then free to recycle back to the cell surface and bind to additional LDL particles, clearing them from the blood.² The ability of LDLRs to be recycled is key to the liver’s ability to lower plasma LDL-C levels.

PCSK9 regulates the recycling of LDLRs by targeting the LDLR for degradation³

While HMG-CoA reductase plays a critical role in cholesterol biosynthesis, PCSK9 plays a critical role in cholesterol metabolism.^4,5 By promoting LDLR degradation within hepatocytes, PCSK9 reduces the concentration of LDLRs on the hepatocyte surface, resulting in increased plasma LDL-C levels.³

SOURCE

AMGEN Cardiovascular

http://www.cholesterolneversleeps.com/what-is-pcsk9.html

Over 20 related articles published on PCSK9 in Cholesterol Regulation on this Open Access Scientific Journal, include the following:

https://pharmaceuticalintelligence.com/?s=PCSK9

and

Series A: e-Books on Cardiovascular Diseases

Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC

Posted in Atherogenic Processes & Pathology, Cardiovascular Research, Epigenetics and Cardiovascular Risks, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy | Leave a Comment

Comments RSS

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular

PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular